Compare Abeona Therapeutics Inc (ABEO) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares 0 3 Month Treasury Bond ETF trades at $100.47. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SGOV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $100.74 |
52-Week Low | $4.17 | $100.28 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.44 with no daily change, reflecting its stable, cash-equivalent nature. Technical indicators signal a bearish trend from moving averages but neutral oscillators, while support and resistance cluster tightly at $100. The ETF offers a low 0.09% expense ratio and yields around 3.54–3.65%, attracting investors seeking short-term Treasury exposure amid rate uncertainty, as highlighted in recent financial news comparing it to peers like BIL.
The outlook for SGOV remains favorable for risk-averse investors prioritizing capital preservation and modest yield, with inflows into bond ETFs surging 60% year-over-year per CNBC (2026-06-25). Key risks include potential Fed rate hikes that could pressure short-term yields and inflation concerns, though its ultra-short duration minimizes interest rate sensitivity compared to longer bonds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
